Hsbc Holdings PLC Acquires 28,878 Shares of Voyager Therapeutics, Inc. $VYGR

Hsbc Holdings PLC grew its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 74.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 67,903 shares of the company’s stock after acquiring an additional 28,878 shares during the quarter. Hsbc Holdings PLC owned 0.12% of Voyager Therapeutics worth $229,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of VYGR. Cubist Systematic Strategies LLC bought a new stake in shares of Voyager Therapeutics in the fourth quarter worth about $29,000. Tower Research Capital LLC TRC increased its holdings in shares of Voyager Therapeutics by 133.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after acquiring an additional 3,077 shares in the last quarter. CWM LLC increased its holdings in shares of Voyager Therapeutics by 856.3% in the first quarter. CWM LLC now owns 10,471 shares of the company’s stock worth $35,000 after acquiring an additional 9,376 shares in the last quarter. Privium Fund Management B.V. bought a new stake in shares of Voyager Therapeutics in the first quarter worth about $73,000. Finally, Tema Etfs LLC bought a new stake in shares of Voyager Therapeutics in the fourth quarter worth about $85,000. 48.03% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Wedbush lowered their price target on Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $13.25.

Voyager Therapeutics Price Performance

VYGR stock opened at $4.24 on Friday. The stock has a market capitalization of $235.19 million, a P/E ratio of -2.29 and a beta of 0.90. The business has a 50-day moving average of $3.37 and a 200-day moving average of $3.42. Voyager Therapeutics, Inc. has a fifty-two week low of $2.64 and a fifty-two week high of $8.27.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.09). The firm had revenue of $5.20 million for the quarter, compared to analyst estimates of $9.50 million. Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%. Equities analysts expect that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.